Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study

被引：55

作者：

Cunningham, David

Tebbutt, Niall C.

Davidenko, Irina

Murad, Andre M.

Al-Batran, Salah-Eddin

Ilson, David H.

Tjulandin, Sergei

Gotovkin, Evgeny

Karaszewska, Boguslawa

Bondarenko, Igor

Tejani, Mohamedtaki Abdulaziz

Udrea, Anghel Adrian

Tehfe, Mustapha Ali

Baker, Nigel

Oliner, Kelly Smith

Zhang, Yilong

Hoang, Tien

Sidhu, Roger

Catenacci, Daniel Virgil Thomas

机构：

[1] Royal Marsden Hosp, Sutton, Surrey, England

[2] Austin Hlth, Melbourne, Vic, Australia

[3] Krasnodar City Oncol Ctr, Krasnodar, Russia

[4] Univ Fed & Minas Gerais, Hosp Clin, Horizonte, Brazil

[5] Univ Canc Ctr, Krankenhaus Nordwest, Frankfurt, Germany

[6] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[7] Russian Canc Res Ctr, Moscow, Russia

[8] Publ Hlth Ivanovo Reg Oncol Dispensary, Reg Budgetary Inst, Ivanovo, Russia

[9] Przychodnia Lekarska Komed Oddzial Jednego Dnia, Konin, Poland

[10] Communal Inst Dnipropetrovsk City Multifield Clin, Dnepropetrovsk, Ukraine

[11] Univ Rochester Med Ctr, James P Wilmot Canc Ctr, Rochester, NY USA

[12] SC Medisprof SRL, Cluj Napoca, Romania

[13] Ctr Hosp Univ Montreal Notre Dame, Montreal, PQ, Canada

[14] Amgen Ltd, Cambridge, England

[15] Amgen Inc, Thousand Oaks, CA 91320 USA

[16] Univ Chicago, Chicago, IL 60637 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.4000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4000

引用

页数：1